TCell

AstraZeneca is expanding into the T cell engager market with its acquisition of TeneoTwo. The small biotech just recently sold off two of its sub-companies to Abbvie and Amgen, as well as raising $60 million in funding to maintain some of the its remaining operations under its control. Astrazeneca is purchasing the TeneoTwo to pick up one of its main drugs.